Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies Authors: Bisma Shahid, Muhammad Tauseef Sultan, Ahmad Mujtaba Noman, Tadesse Fenta Yehuala, Irum Nafees, Muhammad Maaz, Aroob Fatima, Adnan Amjad, Hassan Raza Published: 2026 ABSTRACT AbstractBackgroundPlant-based bioactive compounds, particularly kaempferol and quercetin, exhibit notable anti-inflammatory and anticancer potential.MethodsThis systematic review evaluates experimental evidence on the effects of kaempferol and quercetin, in pure and isolated forms, against lung, breast, and colorectal cancers using in vitro and in vivo models. A systematic search of PubMed, Google Scholar, Taylor & Francis, and Wiley Online Library was conducted in October 2025 following PRISMA guidelines. Studies investigating pure kaempferol or quercetin in human-derived cancer cell lines and animal models were included, while clinical and combination studies were excluded. Only quercetin-based in vivo studies met eligibility criteria. Out of 377 identified records, 24 studies were included.ResultsBoth compounds consistently reduced cancer cell viability, induced apoptosis. They inhibited proliferation and migration by modulating the PI3K/Akt, MAPK, NF-κB, and p53 pathways across breast, lung, and colorectal cancer cell lines. Among the included studies, 16 were in vitro, and 8 were in vivo, with predominantly low risk of bias, indicating robust methodological quality.ConclusionOverall, kaempferol and quercetin demonstrate strong anticancer activity in preclinical models, highlighting their promise for cancer prevention and management. However, well-designed clinical trials are needed to confirm their potential therapeutic relevance.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-026-04901-9.Keywords: Kaempferol, Quercetin, Lung cancer, Breast cancer, Colorectal Cancer, In vitro and in vivo Background Cancer, the multiplication of abnormal cells, is a challenging condition in the landscape of global health, with its intricate pathogenesis and diverse clinical manifestations, posing substantial impediments to effective treatment and prevention. It is globally prevalent, with an estimated 20 million new cases, along with ~ 9.7 million mortalities, documented in 2020 [1]. The clinical, social, and economic burden has been extensively compromised by the rising figures of cancers, and it is predicted that cancer will surpass other maladies to cause deaths [2]. Multiple factors, such as sedentary lifestyles, irregular eating patterns, poor dietary choices, smoking, tobacco and smoking, inheritance, genetic mutation (TP53, PTEN), drug resistance, prolonged inflammation, and viral infections, contribute to the development and proliferation of tumor cells [3, 4]. Cancers, including prostate, breast, lung, stomach, colorectal, skin, bladder, liver, pancreatic, bone, and melanoma, are age- and sex-oriented, which are developed with diverse severity [5]. Therefore, cancer severity and its aggravating burden highlight the obstinacy to develop alternative and effective regimens [6]. Modernization, industrialization, and digitalization have significantly subsidized the development of advanced healthcare systems, offering versatile strategies, such as surgery, chemotherapy, radiotherapy, hormone replacement therapy, and immunotherapy, to manage cancer pathogenesis, invasion, metastasis, and proliferation. However, the associated adverse consequences in the form of reduced specificity, drug resistance, and cognitive impairments, have further advanced the need to develop innovative management strategies [5]. Medicinal plants and their bioactive compounds have gained distinctive recognition in this regard due to their multi-target activity, limited toxicity, and better bioavailability [7]. Flavonoids, particularly quercetin and kaempferol, are the special class of bioactive compounds, abundantly found in fruits (grapes & citrus), vegetables (broccoli & onion), tea, and herbs, which manifest health-promoting attributes, such as antioxidant, anti-inflammatory, anticancer, antimicrobial, cardioprotective, and neuroprotective [8, 9]. They attenuate cancer metastasis by inducing apoptosis via mitochondrial and caspase-mediated pathways, regulate essential signal transducers, such as the MAPK family (MEK-ERK, p38 MAPK, JNK, and ERK1/2) and certain activities, like angiogenesis and metastasis, suppress tumor cell proliferation, and promote cell cycle arrest [10]. Figure 1 shows the summary of anticancer mechanism of kaempferol and quercetin. Schematic overview of dietary sources and anticancer effects of kaempferol and quercetin. Flavonoids, abundant in fruits and vegetables, exhibit antioxidant and anti-inflammatory properties and modulate key signaling pathways including PI3K/Akt, NF-κB, MAPK, and p53, thereby promoting apoptosis and inhibit tumor cell proliferation and migration The multi-target activity of kaempferol and quercetin in cancer treatment and chemoprevention have encouraged to conduct studies for their therapeutic validation. Moreover, epigenetic divergence could be reduced by supplementing flavonoids in colorectal cancer models [3]. Although kaempferol and quercetin have anticancer effect in breast, lung, and colorectal cancer (in vitro), however, data regarding human studies have been limited. The purpose of this systematic review was to analyze the fundamental molecular mechanisms of kaempferol and quercetin in relation to oncogenesis, identifying existing research gaps, and emphasizing the importance of comprehensive studies to integrate in vivo findings and their clinical relevance against real-world applicability in lung, breast, and colorectal cancer. Methods Reporting and protocol The methodology is transparent and reproducible, which is adhered to the PRISMA 2020 guidelines [11]. The protocol is based on the PICO framework [12], that stipulates the population, intervention, comparator, and outcomes of interest. Each step of the article screening, data extraction, and analysis was performed manually and transparently. Population The included studies investigated malignancy cell lines (MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, SK-BR-75-30, BT549, BT474, MCF-10AT, GLC-82, H1229, HCT-116, HT-29) and mammalian models, representing breast, lung, and colorectal cancers. All models were experimentally validated to evaluate tumor growth, proliferation, apoptosis, migration, and associated mechanisms. Intervention The treatment was the administration of pure kaempferol and quercetin at diverse concentrations for different time intervals, either directly in cell culture systems or through oral, intraperitoneal, or intravenous routes in rodent models. Moreover, studies regarding the synergistic interaction of these compounds with other compounds, traditional formulations, drugs, and plant extracts were eliminated to provide accurate data and findings. Comparator The research papers mainly focused on comparator groups, containing tumor cells that were not subjected to vehicle mixtures saline or DMSO (Dimethyl Sulfoxide) to dissolve kaempferol and quercetin. These comparators are used to control the study, differentiate the effects of the targeted phytochemicals on the biological activity and the effect formed by the solvent or the control activity of the cell. Moreover, no placebo or any standard drug was used except the pure kaempferol or quercetin. Outcomes The selected studies revealed that kaempferol and quercetin have potent anticancer properties with several cellular and molecular actions. The main findings were the decreased cell viability, tumor growth, apoptotic induction, cell cycle arrest, and migration and invasion suppression, as supported by MTT, CCK-8, colony formation, and flow cytometry. These compounds regulated oncogenic pathways, such as PI3K/Akt, MAPK/ERK, NF-kβ, EMT-related cascades, and induced oxidative stress-mediated cytotoxicity. Kaempferol and quercetin have increased pro-apoptotic (Bax and cleaved caspase-3/9) and decreased anti-apoptotic (Bcl-2) proteins, demonstrating their capacity to alter cellular balance for apoptosis induction. These effects suppress tumor cell growth, induce apoptosis, and suppress oxidative and inflammatory markers in tumor tissues. In a nutshell, the results suggest that kaempferol and quercetin can be used synergistically to regulate cell cycle, oxidative stress, and survival pathways to inhibit tumor invasion and metastasis. Search strategy The data was searched from the online databases, including Google Scholar, PubMed, Wiley Online Library, and Taylor and Francis, from the published articles during the specific time (2016–2025) by using Medical Subject Headings (MeSH) and free-text keywords related to compounds and targeted cancers. The main search terms were kaempferol and quercetin in combination with breast cancer, lung cancer, or colorectal cancer, and experimentation filters (in vitro/in vivo, animal model, cell line, xenograft, mice/rat, and cell lines A549, HCT116, MCF-7, TNBC, H1229, HCT116. The search was abridged using the Boolean operators (AND & OR) and manually reviewed reference lists of pertinent articles to detect irrelevant study in the database search. All original peer-reviewed full-text research articles published in English were taken into consideration, while the retrieved papers were exported into Zotero to eliminate duplications. Moreover, Mendeley aids in managing references. Afterwards, the selected articles were systematically screened to customize inclusion and exclusion criteria. The whole search process was coded and done comprehensively, following PRISMA guidelines. Eligibility criteria A clear and specific eligibility criteria for the selection of studies was developed by focusing on the individual anticancer potential of quercetin and kaempferol against breast, lung, and colorectal cancer. Inclusion criteria The screening of studies will be conducted in accordance with the following inclusion criteria (I) Experimental studies involving in vitro human-derived cancer cell lines and in vivo mammalian models (mice or rats); (II) The use of kaempferol or quercetin as pure, isolated compounds; (III) Breast, lung, and colorectal cancer; (IV) Evaluation of cellular or molecular events, such as proliferation, apoptosis, migration, invasion, oxidative stress, and the regulation of signaling pathways; (V) Availability of full-text, peer-reviewed original research articles published between 2016 and 2025. Exclusion criteria Exclusion criteria was strictly followed to ensure scientific rigor and relevance: (I) Studies that involved kaempferol and quercetin with other phytochemicals, plant extracts, decoctions, multi-component mixtures or traditional medicinal formulations; (II) in silico studies, such as molecular docking, network pharmacology or computational simulations; (III) Studies using non-human cell lines and non-mammalian models (zebrafish, insect, and bacterial systems); (IV) Clinical trials, reviews, editorials, conference abstracts, or articles lacking original experimental data; and (V) Retracted, duplicate, or inaccessible publications that did not meet the quality standards for data extraction and synthesis. Screening of articles The screening process was organized based on the PRISMA guidelines, as stated in the data in S1Table. The preliminary search of articles was done from the selected databases. The duplicate and irrelevant articles were excluded, and the remaining articles were evaluated based on their titles and abstracts. Furthermore, non-original research articles, review papers, and studies other than the targeted cancers were discarded. Conclusively, articles fulfilling the inclusion and exclusion criteria were included, while studies on combination therapies and computational methods were removed. Risk of bias There is no standardized risk of bias assessment tool tailored for in vitro investigations. Therefore, a custom risk of bias tool, Risk-of-bias VISualization (ROBVIS), was developed by Rahim et al. [13] to evaluate the methodological quality of in vitro and in vivo studies, employing human cancer cell lines. Seven domains were measured: (i) cell line authentication, (ii) controls, (iii) treatment details, (iv) replication, (v) statistical analysis, (vi) assay validity, and (vii) conflict of interest. The studies were characterized as “low risk”, “high risk”, or “unclear risk” in each domain, as well as “overall risk”. The findings were illustrated via the Robvis tool (generic version) to develop traffic light and summary plot visualizations, along with percentage distributions for each domain and overall rating. The overall risk of bias for each study was determined based on the number and severity of domain-level judgments. Studies with all domains rated low, or only one marked as unclear, were categorized as low risk. If two or more domains were unclear, the overall risk was judged as unclear. If two or more domains are mentioned as having no information, the overall risk was judged as high [14]. Data extraction Manual extraction of data was used to achieve precision. Databases were thoroughly searched to identify significant methodological and outcome-based variables regarding the effects of kaempferol and quercetin on breast, lung, and colorectal cancers. Predefined data fields were used according to their relevance, including study design, cancer type, utilized cell lines, dosage, exposure duration, involvement of signaling processes, and the main outcomes of selected compounds. The findings were synthesized critically besides descriptive extraction by identifying studies based on molecular pathways, cancer subtypes, and the biological endpoint. The repetitive mechanistic patterns, including PI3K/Akt, MAPK/ERK, NF-кB, and EMT -related signaling pathways, were recognized and contrasted between the experimental paradigms to establish consistency and reproducibility. The strength and coherence of the whole evidence were also reviewed on differences in experimental designs, dose ranges, and model systems. The interpretation of outcomes is reported in Table 1, which shows the descriptive characteristics of the included studies. Table 1Descriptive characteristics of included studies (n = 24)Sr#ReferencesCancer cell lineTreatmentDoseDurationPathwayMechanismTests/ assayOutcomes1 [15]Breast (MCF-7), Lung (A549)Kaempferol6.25–100 µg/mL72 hCell viability pathways↓ proliferationMTT assay for cell viability.Cytotoxic, anti-proliferative (IC₅₀ MCF-7: 90.28 µg/mL)2 [16]Breast (MCF-7)KaempferolTriclosan (TCS), E2 (17β-estradiol), ICI 182,780 (ER antagonist)25–50 µM24–72 hER signaling, EMT↑ N-cadherin, Snail, Slug; ↓ E-cadherin, MMP-2/9Wound-healing assay, transwell migration/invasion assay, and Western blot assay.↓ migration, ↓ invasion3 [17]Breast (MCF-7)Kaempferol20–80 µM24 h–3 weeksApoptosis (Bcl2/Bax, PARP)↓ Bcl2, ↑ Bax, ↑ PARP cleavageMTS assay,soft agar colony formation assay, Fluorescence staining (DAPI), Western blotting.Apoptosis, ↓ colony formation4 [18]Breast (MCF-7, MDA-MB-231, SK-BR-3)Kaempferol10–200 µM1–6 hRhoA/Rac1, EMT↓ RhoA, ↓ Rac1; modulation of EMT markersWound-healing, cell invasion, Rho activation, Pulldown, and Western blot assay↓ invasion5 [19]Breast (ZR-75-30, BT474)Kaempferol10–100 µM24–72 hIQGAP3 / ERK1/2↓ IQGAP3; ↑ p-ERK1/2; ↑ Bcl2; ↓ BaxReal-time PCR, Cell Counting Kit-8 (CCK-8), Flow cytometry (FCM), Western blot.↓ proliferation, ↑ apoptosis6 [20]TNBC (MDA-MB-231, BT474)Kaempferol43–50 µM48–72 hCaspase pathway, DNA damage↑ caspase-3/9, ↑ γH2AX, ↑ p-ATMMTS assay, DAPI staining, Western blotting, Flow cytometry (PI staining), Hoechst 33,258, annexin V/PI staining.Apoptosis, G2/M arrest7 [21]Colorectal (HCT116)Kaempferol20–40 µM24–72 hOGT–collagen axisTargets modulation of O-GlcNAcylationTranswell, EdU, SRB assay, Western Blot↓ proliferation8 [22]Lung (GLC-82, HTB-182)Quercetin50 µM24–48 hmiR-16-5p/WEE1↑ miR-16-5p, ↓ WEE1qRT-PCR, CCK-8 assay, Western blot, dual-luciferase reporter assay↑ radiosensitivity9 [23]Lung (A549, H1299)Quercetin12.5–100 µM24 hSIRT1/AMPK↑ autophagy signalingCCK-8, Western blot, RT-PCR, TEM, LC3 immunofluorescenceApoptosis via autophagy10 [24]Colorectal (HCT116, HT-29)Quercetin50–150 µM24 hSp1/miR-27a axis↓ Sp1 (via degradation)Cell viability, flow cytometry, Western blot, qRT-PCR, immunofluorescence assay↓ proliferation, apoptosis11 [25]Breast (MCF-7, MDA-MB-231)Quercetin10–100 µM48 hHeat shock proteins, NF-κB↓ Hsp27/70/90, ↑ NF-κB p50MTT assay, Western blot Caspase activity assay, Comet assayApoptosis12 [26]Colorectal (HT-29)Quercetin5–100 µg/mL24 hVEGF/NF-κB↓ VEGF-A, ↓ NF-κB p65MTT Assay, Tubulogenesis Assay, Indirect Immunofluorescence Assay (IFA), Western Blot Analysis.↓ angiogenesis13 [27]TNBC (MDA-MB-231)Quercetin20 µM24–48 hJNK/Foxo3a↑ JNK, ↑ Foxo3a, ↑ p53/p21MTT assay, Flow cytometry, Luciferase assay, Western blot, RTPCRApoptosis, cell cycle arrest14 [28]Lung (PC-9)Quercetin25–100 µM24–48 hMAPK, mitochondrial apoptosis↑ p38, ↓ ERK, ↑ cytochrome cMTT assay, and Western BlotApoptosis15 [29]Breast (MCF-10AT, MCF-7)Quercetin5–120 µM24–48 hJAK/STAT1↑ p-JAK2, ↑ STAT1, ↓ PD-L1MTT assay, Apoptosis assay, Flow cytometry, CFDA SE (CFSE) assay, Western blot analysisApoptosis, immune modulation16 [30]TNBC (MDA-MB-231, BT-549)Quercetin10–17 µM24–72 hORM2↓ ORM2Cell viability assay (CCK-8)↓ viability17 [31]TNBCQuercetin30 mg/kg21 daysβ2-AR/ERK1/2↓ ERK signalingCCK-8, flow cytometry↓ tumor growth, metastasis18 [32]TNBC (MDA-MB-231, MDA-MB-468)Quercetin10–35 µM24–72 hIGF1/IGF1R↓ EMT signalingCCK-8 assay, Western Blot, Transwell invasion assay↓ aggressiveness19 [33]Breast Cancer (MCF-7, MDA-MB-231)Quercetin37 µM; 50 mg/kg37 µM; 50 mg/kgCYP3A4 pathway↓ CYP3A4CCK-8, MTS, flow cytometry,↓ proliferation, invasion20 [34]Breast Cancer (CDK4/6 inhibitor resistant)Quercetin0–160 µM24, 48, and 72 h (Viability); 24 h (Transwell)circHIAT1/miR axismodulation of EMT pathwayCCK-8 assay, Transwell, Western Blot↓ resistance, ↓ EMT21 [35]BreastQuercetin50 mg/kg14 daysVitamin D receptor↑ VDRbiochemical analysis↓ inflammation, fibrosis22 [36]BreastQuercetin0.1% diet21 daysCircadian pathwaysPrevention of metastasis and modulationtumor growth and lymph node metastasis investigation↓ metastasis23 [37]Lung (NSCLC)Quercetin10–50 µM24–48 hAkt/ADAM9↓ Akt, ↓ ADAM9MTS assay, Transwell invasion, wound healing, Western Blot↓ invasion24 [38]Lung (EGFR mutant)Quercetin~ 30 µM24–72 hGrowth signalingGrowth suppressionCell viability assay (CCK-8)↓ proliferationTable 1 presents a summary of the mechanistic activities of kaempferol and quercetin on different cancer cell models. Dosage ranges, exposure duration,and modulation of particular signaling pathways linked to cell survival, apoptosis, epithelial–mesenchymal transition, and metastasis are highlighted. Arrows (↑ upregulation, ↓ downregulation) indicate the manner in which molecular regulation is proceeding. Since the majority of the evidence comes from in vitro tests, preclinical research should be taken into consideration when interpreting it. Descriptive characteristics of included studies (n = 24) Kaempferol Triclosan (TCS), E2 (17β-estradiol), ICI 182,780 (ER antagonist) MTS assay, soft agar colony formation assay, Fluorescence staining (DAPI), Western blotting. Table 1 presents a summary of the mechanistic activities of kaempferol and quercetin on different cancer cell models. Dosage ranges, exposure duration,and modulation of particular signaling pathways linked to cell survival, apoptosis, epithelial–mesenchymal transition, and metastasis are highlighted. Arrows (↑ upregulation, ↓ downregulation) indicate the manner in which molecular regulation is proceeding. Since the majority of the evidence comes from in vitro tests, preclinical research should be taken into consideration when interpreting it. Results Study selection The process of searching and selecting relevant literature was led by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework [11]. A total of 377 records were initially retrieved through searches from the four databases: PubMed (n = 198), Google Scholar (n = 153), Taylor & Francis (n = 21), and Wiley Online Library (n = 5). After the removal of duplicate records and irrelevant entries (n = 52), 72 articles were retained for title and abstract screening. During this screening phase, 15 studies were excluded due to irrelevant data, retaining 57 articles for full-text eligibility assessment. Of these, 33 studies were excluded, including 27 review articles and 6 retracted publications, based on predefined exclusion criteria. Finally, 24 studies meet the eligibility criteria, and are considered for organizing systematic review. The PRISMA flowchart summarizes the selection process, detailing number of records initially identified and those remaining after screening, evaluation, and inclusion. None of the identified in vivo or xenograft studies investigating kaempferol in lung, colorectal, or breast cancer met the predefined inclusion criteria; therefore, only in vivo studies evaluating quercetin were included in the final analysis. Figure 2 presents the PRISMA flow diagram of the literature search process. PRISMA flow diagram of the literature search process Study characteristics The analyzed works were distributed in the 2016-2025 period. Articles were chosen only in English. The selected studies originated from eight countries: India [15,35], China [17,18,20–23,29–31,33,34,39], Korea [16,27,28], Japan [36], Thailand [26], Taiwan [32,37,38], Turkey [25], and Italy [24]. The research was carried out inEast, South, and Southeast Asia, as well as Southern Europe and Western Asia, illustrating geographically diversified research. Kaempferol and Quercetin dosage, treatment duration, and cell lines used in the selected in vitro and in vivo studies were varied. There are 8 in vivo and 16 in vitro studies, comprising various cancer cell lines, including MCF-7, A549, H1299, HCT116, HT-29, MDA-MB-231, BT474, T24, ZR-75-30, and TNBC. Although kaempferol-related in vivo and xenograft studies were initially screened, none fulfilled the inclusion criteria. Consequently, the final synthesis comprised only in vivo studies evaluating the potential of quercetin. Table 1 summarizes all the characteristics and key findings of the relevant study, which were carefully considered in the review. Risk of bias assessment The risk of bias (RoB) assessment for the included in vitro studies is summarized in Figs. 3 and 4, which show the Customized Risk of Bias assessment of included studies. The risk of bias assessment for the included in vivo studies is summarized in Fig. 5, which shows the SYRCLE’s risk of bias tool for animal studies [39]. There are 8 in vivo studies of quercetin for which the analysis revealed that the preclinical literature was defined as low overall Bias (75.0%), moderate, and high (12.5% and 12.5%, respectively). However, the core of this low-risk designation is compromised by the presence of vague ratings in critical domains, especially areas related to randomization and allocation concealment. Such systemic absence of transparency indicates the underestimation of actual methodological risk. For 16 in vitro studies, the evaluation showed 87.5% (14/16) as low overall risk of bias, and 6.25% (1/16) as High and 6.25% (1/16) as unclear. Although the majority of the designations were low risk, a number of areas had recurrent Unclear things, the most prominent of which were in Experimental Replication, Conflict of Interest and Cell Line Authentication. Such limitations reflect the lack of full methodological transparency, especially related to reproducibility and disclosure. Consequently, the high-proportion of low-bias scores may enhance the actual internal validity of the selected in vitro evidence, suggesting that the optimistic bias profile is largely attributable to superior reporting practices rather than experimental robustness. Collectively, these results showed that most of the encompassed in vitro and in vivo studies were of good quality, and the weaknesses were associated with experimental repetition, complete coverage of results, and disclosure of conflict statements [14]. Traffic light plot of Customized Risk of Bias (ROB) assessment of in vitro studies. Risk of bias assessment of the included in vitro studies across seven methodological domains (D1–D7), including cell line authentication, controls, treatment reporting, replication, statistical rigor, assay validity, and conflict of interest. Most studies were rated as low risk across domains, indicating generally strong methodological quality. A few studies showed unclear or no information in selected domains, and one study demonstrated an overall high risk of bias Summary plot of Customized Risk of Bias (ROB) assessment of in vitro studies. Domains, including appropriate controls, assay validity, statistical rigor, and cell line authentication, were rated as low risk. Some concerns were noted for experimental replication and conflict of interest, with a small proportion categorized as unclear or lacking information Traffic light plot of SYRCLE’s risk of bias tool for in vivo studies. Risk of bias assessment of the included studies across ten domains (D1–D10),including sequence generation,allocation concealment, blinding, outcome assessment,incomplete data, and selective reporting. Green circles indicate low risk,yellow indicate unclear risk, and red indicate high risk of bias Anti-proliferative effects of kaempferol Kaempferol demonstrated anti-proliferative activity against the breast and lung cancer cell lines, particularly the proliferation of MDA-MB-231 cells [20] and growth suppression of BT474 and ZR-75-30 cells via downregulating IQGAP3 [19]. Moreover, the dose-dependent cytotoxic effects were observed in A549 lung and MCF-7 breast cancer cell lines [15]. Furthermore, MTS assays validated decreased cell viability and interfered with growth-related pathways [17]. Notably, kaempferol was more potent in triple-negative breast cancer cells (IC50 = 43 µmol/L), whereas ER-positive BT474 cells showed reduced sensitivity (IC50 > 100 µmol/L) [20]. Induction of apoptosis Apoptotic bodies and morphological changes were detected in MCF-7 cell lines, which were accompanied by Bcl-2 downregulation and cleaved PARP activation [17]. Hu et al. [19] demonstrated that kaempferol induce apoptosis by suppressing ERK1/2 pathway via IQGAP3 inhibition as well as by elevating γH2AX, cleaved caspase-3 and − 9 expression [20]. EMT and cytoskeletal pathway modulation Kaempferol significantly inhibited cancer cell migration and invasion across breast cancer models, particularly by targeting key cytoskeletal pathways. It reduced RhoA and Rac1 activity in MDA-MB-231 cells and countered triclosan-induced migration in MCF-7 cells by downregulating MMP-2/9 and cathepsins B and D. Moreover, it inhibited RhoA phosphorylation and reversed HER2-driven signaling modifications in HER2-overexpressing models, while suppressing RhoA (a signaling cascade that primarily regulates the organization of the actin cytoskeleton within cells) and Rac1 activation in triple-negative and receptor-silenced cell lines. Additionally, kaempferol inhibited EMT, a key step in metastasis. Moreover, it restored epithelial integrity by upregulating cadherin and reducing mesenchymal markers, thus preventing the shift toward an invasive phenotype [16]. Effects on specific cancer subtypes Subtype-specific responses to kaempferol were reported by Zhu et al. [20], observed stronger anti-proliferative effects in TNBC cells (MDA-MB-231) as compared to hormone receptor-positive BT474 cells. Targeting OGT–Hsp47–collagen axis to inhibit colorectal cancer progression Kaempferol suppresses the pathogenesis of colorectal cancer by directing O-GlcNAcylation pathway, particularly OGT Hsp47 collagen axis. It interacts with O-GlcNAc transferase (OGT) at His-901 and Asp-925 to inhibit the enzymatic activity and production of UDP-GlcNAc. This suppresses O-GlcNAcylation and Hsp47 at Ser76, a chaperone involved in type I collagen maturation. This subsequent inhibition of collagen synthesis and remodeling of extracellular matrix restricts tumor growth, migration, and metastasis. Therefore, the anticancer activity of kaempferol involves in metabolic restructuring of colorectal cancer, especially mediated by O-GlcNAc [21]. Inhibition of metastasis and epithelial-mesenchymal transition (EMT) Quercetin is effective in preventing the aggressive and migratory phenotype, related to cancer development by acting on important signaling nodes. Chang et al. [37] revealed that quercetin inactivates metastatic potential and cell motility in non-small cell lung cancer (NSCLC) by suppressing Snail-mediated Akt 2 activation and ADAM9, while enhancing the tumor suppressor maspin. Similarly, Chen et al. [32] depicted that quercetin inhibits phenotype, cellular migration, and metastatic potential in TNBC by suppressing IGF1/IGF1R axis, thus inhibiting EMT activation. Furthermore, quercetin inhibits the progression of stress-induced TNBC via blocking 3β2-AR/ERK1/2 signaling pathway. Furthermore, quercetin effectively inhibits aggravated TNBC growth and pulmonary metastasis by inhibiting 4β2-AR/ERK1/2 cellular signaling cascade [31]. Reversal of drug resistance and non-coding RNA modulation Quercetin is effective in subduing acquired therapeutic resistance by vanquishing third-generation tyrosine kinase inhibitor (TKI)-resistant human cancers (38). Quercetin inhibits tumor growth, cell viability, and EMT in NSCLC cells by harboring EGFR-C797S mutation. Moreover, Li et al. [34] further reflected quercetin ability to inhibit EMT and overcome CDK4/6 resistance. Targeting metabolic and systemic pathways Quercetin has a complex mechanism of action, ranging from direct molecular-targeting effects to a systemic protective action through hormonal pathways. Liu and Chen [30] revealed the inhibitory effect of quercetin against TNBC, which is mediated by its binding to Orosomucoid 2 (ORM2) protein, consequently reducing cell viability and tumor growth in animal models. Furthermore, quercetin suppresses CYP3A4 activity, which in turn activates the transformation of arachidonic acid and inhibits the nuclear translocation of phosphorylated Stat3 [33]. At the systemic level, Sannappa et al. [35] reported that quercetin promotes Vitamin D Receptor (VDR) in breast cancer cells in an in vivo model, thereby decreasing hepatic inflammation and fibrosis. Moreover, Numata et al. [36] demonstrated that dietary quercetin inhibits lymph node metastasis in a rodent model by disrupting circadian rhythms and consequently inhibiting the Per2 gene. Cytotoxicity, apoptosis, and cell cycle modulation Quercetin, a cytotoxic agent, promotes programmed cell death and cell cycle progression via modulating intrinsic signaling pathways in triple-negative breast cancer (TNBC) cells by targeting Foxo3a [27]. The pro-apoptotic activity of quercetin against EGFR-mutant lung cancer cells is stimulated by activating mitochondrial pathway to activate caspase and p38 MAPK signaling pathway [28]. Furthermore, quercetin is a potent anti-heat shock protein (Hsp) inhibitor, thereby inducing apoptosis in human breast cancer cells [25]. Modulation of angiogenesis and immune microenvironment Quercetin has the potential to control tumor microenvironment by focusing on factors involved in tumor growth and immune evasion. It suppresses tumor-induced angiogenesis in colorectal cancer by downregulating EGF-A/VEGFR2 pathway [26]. Moreover, it was also discovered that quercetin has immunomodulatory activity in breast cancer, which is manifested by suppressing JAK/STAT1 pathway. The activity is further promoted by the synergistic interaction of quercetin with gamma-delta T cells [29]. Sp1-miR-27a axis regulation Quercetin has a dual action in counteracting the Sp1-miR-27a axis in colorectal cancer cells, which explains the specificity of the microRNA signaling pathway as the anticancer mechanism [24]. Apoptosis, autophagy, and radiosensitivity control Quercetin showed anti-proliferative activity against the lung cancer cells by radio-sensitization and targeting the apoptotic mechanism. A. miR-16-5p/WEE1 axis regulation and radio sensitization Quercetin, as a radio-sensitizing agent in non-small cell lung cancer (NSCLC) cells, can regulate the miR-16-5p/WEE1 axis [22]. B. SIRT1/AMPK signal transduction and pro-apoptotic autophagy An independent experiment on human lung cancer (A549 and H1299) cell lines revealed that quercetin triggers pro-apoptotic autophagy through the SIRT1/AMPK signaling pathway. According to Guo et al. [23] quercetin is able to alter the main metabolic and survival pathways to induce cell death in these cell lines. Discussion Kaempferol and quercetin, the naturally occurring flavonoids, have garnered considerable attention in recent years due to their chemo-protective properties. This systematic review evaluated in vitro and in vivo (animal and xenograft models) studies, with their primary focus on lung, breast, and colorectal cancer cell lines. Collectively, the integrated evaluation of mechanistic convergence, pathway modulation, and reproducibility across independent studies strengthens the biological plausibility of these flavonoids, while also revealing translational and methodological gaps. It exhibits anticancer potential by modulating key signaling pathways and gene expression, resulting in anti-proliferative, pro-apoptotic, anti-metastatic, and anti-inflammatory attributes. Therefore, these findings should be interpreted as mechanistic and exploratory rather than directly translatable to therapeutic application. Current evidence is predominantly derived from in vitro models, with limited in vivo validation and clinical trials. There is an evident imbalance in the level of evidence between the two compounds. Although quercetin has been examined in cell and animal models, kaempferol evidence is limited to in vitro studies. This limitation is caused by the lack of research applicability to the predetermined inclusion criteria, instead of the selective exclusion. Therefore, the biological effects of kaempferol can be viewed as mechanistic and exploratory. The lack of in vivo validation represents a critical gap, as it limits the ability to assess pharmacokinetic behavior, systemic interactions, and overall physiological relevance. This gap should be addressed by conducting well-designed animal studies to take kaempferol to translational and clinical research. Figure 6 presents the anticancer mechanism and associated signaling pathways of kaempferol and quercetin. Proposed molecular mechanisms of kaempferol and quercetin in cancer models. Flavonoids suppress tumor growth by inducing G2/M cell cycle arrest, promoting DNA damage, and promoting apoptosis. Moreover, also inhibits EMT and metastasis while modulating key signaling pathways, oxidative stress, and inflammatory mediators Lung cancer Studies have validated the effect of kaempferol in inhibiting lung cancer (A549 and H1299) proliferation by inducing apoptosis through improving Bax/Bcl-2 & caspase-3 activation, as well as the release of cytochrome c [40]. Recent data have also emphasized kaempferol’s potential in overcoming resistance to tyrosine kinase inhibitors (TKIs) in NSCLC. Moreover, kaempferol demonstrated significant anticancer activity in both TKI-sensitive (HCC827, H2073) and TKI-resistant (HCC827C1, HCC827C2, H1993) NSCLC cell lines. Furthermore, kaempferol administration at a 200 µM dose for colony formation assays and 50 µM for MTT assays for consecutive seven days resulted in a dose-dependent inhibition of cancer cell proliferation. Notably, kaempferol exhibited enhanced selectivity against the TKI-resistant H1993 cell line, while having a limited influence on the TKI-sensitive H2073 line. This suggests that kaempferol exerts its effects through alternative pathways that bypass traditional resistance mechanisms, offering a promising strategy for combating progressive NSCLC with acquired resistance to TKIs [41]. Additionally, Hu et al. [19] depicted that IQGAP3 downregulated kaempferol-induced cytotoxicity in NSCLC cells, thereby demonstrating IQGAP3 to mediate kaempferol resistance in inducing pharmacological potential. Quercetin (Qc) is a radiosensitizer and metastasis inhibitor in NSCLC, which is regulated by inhibiting Epithelial-to-Mesenchymal Transition (EMT)- a major step of metastasis to upregulate epithelial marker, E-cadherin, and downregulate mesenchymal markers (N-cadherin and vimentin). These anti-metastatic potential acts mechanistically in 2 pathways: (i) a Snail-dependent mechanism in which Qc inhibits EMT transcription factors (Snail and Slug). It has been revealed that snail inhibition results in increasing tumor suppressors, such as maspin, which in turn inhibits Akt (p-Akt) activation. High Snail/high p-Akt is a predictor of poor survival, which is in favor of the clinical relevance of this pathway. (ii) A Snail-independent signal transduction pathway, in which A disintegrin and metalloprotease (ADAM) 9 expression regulates tumor cell invasion, is suppressed. Moreover, Qc promotes ADAM9 inhibition through posttranscriptional regulation [37]. Qc also induces caspase-dependent apoptosis in EGFR mutant NSCLC cells (PC-9), specifically activating caspase-9-dependent mitochondrial pathway, which depends on the release of cytochrome c. Furthermore, the activation (phosphorylation increase) of the p38 MAPK signaling pathway occurs in a dose- and time-dependent manner as a required step in intracellular apoptosis [28]. Moreover, Qc eluded resistance in TKI-resistant NSCLC cells (EGFR C797S mutation, H1975-MS35) by blocking tyrosine kinase AXL receptor as well as activating STAT3. Moreover, Qc also decreases phosphorylated AXL (pAXL) and phosphorylated STAT3 (pSTAT3), which is a significant difference compared to EGFR inhibitory activity. Moreover, it has been observed that AXL inhibition is triggered by Qc in both transcriptional (probably through AP1 and HIF-1α) and posttranscriptional levels [38]. In the case of radiosensitivity, it has been shown that Qc acts on the miR-16-5p/ WEE1 axis, thereby elevating tumor suppressor miR-16-5p expression and inhibiting WEE1 [22]. Furthermore, Qc induces pro-apoptotic autophagy in A549 and H1299 cell lines via SIRT1/AMPK-mediated intracellular pathway [23]. Breast cancer Mechanistic insights into kaempferol-induced growth inhibition and apoptosis in breast cancer The promising anti-metastatic potential of kaempferol has been shown by its dual ability to suppress tumor cell proliferation and induce apoptosis. Londonkar et al. [15] demonstrated a dose-dependent reduction in MCF-7 cell viability, with the IC50 value of 90.28 ± 4.2 µg/mL. Similarly, Yi et al. [17] depicted significant inhibition of MCF-7 cell proliferation at increasing kaempferol concentrations (26.3%, 49.7%, and 77.3% at 20, 40, and 80 µM, respectively), along with reduced colony formation. Mechanistically, kaempferol induced apoptosis by downregulating anti-apoptotic protein Bcl2 and promoting PARP cleavage. This pro-apoptotic shift, involving modulation of the Bcl2 family and enhanced Bax activity, has been consistently reported in breast cancer cells [42, 43]. Targeted anticancer activity of kaempferol in triple-negative breast cancer via DNA damage and cell cycle arrest Kaempferol shows its potential against triple-negative breast cancer (TNBC) cells, which have no targeted treatment, as it does not express estrogen, progesterone, and HER2 receptors [41]. Moreover, Zhu & Xue [20] reported kaempferol selectivity with lowered IC50 = 43 µmol/L in the MDA-MB-231 TNBC cells than the ER-positive BT474 cells (IC 50 > 100 µmol/L). Furthermore, kaempferol promoted cell cycle arrest at G2/M phase and intrinsic apoptotic pathways as evidenced by enhanced annexin V binding and reduced caspase-3 and − 9 pathway. Interestingly, it induced DNA damage by improving γH2AX and phosphorylated ATM (p-ATM), thereby leading to cell cycle disruption and apoptosis. Modulation of ERK signaling via IQGAP3 downregulation The use of kaempferol on major cellular targets provides a further understanding of its anti-breast cancer processes. Hu et al. [19] demonstrated that kaempferol decreased IQGAP3 expression, an oncogene contributing to breast cancer progression, significantly in ZR-75-30 and BT474 cell lines. IQGAP3 overexpression inhibits apoptosis induction due to the activation of p-ERK1/2 and Bcl-2 expression, and the inhibition of Bax. Notably, kaempferol counteracted such effects, which suggests IQGAP3 is a major molecular target by which it regulates ERK-mediated survival signaling and induces apoptosis in breast cancer cells. Suppression of migration and invasion in breast cancer Kaempferol proves to have significant anti-metastatic properties by acting on major processes in the development of breast cancer. It inhibited EMT in MCF-7 cells through restoration of E-cadherin expression and inhibition of mesenchymal markers, and proteolytic enzymes, including MMP-2, MMP-9, cathepsins B and D [16]. In a similar manner, Li et al. [18] established that kaempferol only selectively suppressed migration and invasion in the TNBC cells at low dosage by suppressing RhoA and Rac1 signaling and showed no effect on non-TNBC cells except at higher dosage. These results point to the possibility of kaempferol inhibiting metastatic behavior, especially in aggressive types of breast cancer. Quercetin and breast cancer QC in breast carcinoma (BC) controls a variety of pathways essential to the survival of the cells, their metastasis, and in response to therapy, such as resistance mechanisms and immune modulation. Qc is a Heat Shock Protein (Hsp) inhibitor, which inhibits the expression of Hsp27, Hsp70, and Hsp90 in both ER-positive (MCF-7) and Triple-Negative Breast Cancer (TNBC, MDA-MB-231) cells. Such Hsp depletion causes apoptosis, which is characterized by the activation of caspase-3/7 and cleavage of PARP-1. Qc raises the NF-50 subunit level; however, the overall effect is anti-cancer [25]. Qc inhibits phenotypes of aggression in TNBC by blocking the IGF1R signaling pathway. Qc prevents the phosphorylation of IGF1R and IGF1R downstream targets, Akt and Erk1/2. This represses transcription-driving factors Snail, Slug, and hence reverses EMT [32]. Qc also regulates the autocrine loop through the augmentation of the secretion of IGFBP3 and the suppression of IGF1 secretion. Moreover, Qc suppresses the evolution of chronic stress (epinephrine, E) in TNBC via inhibiting the 2-AR/ERK12 pathway. This inhibits the E-mediated up-regulation of factors of proliferation (c-Myc, PCNA) and migration (MMP-2, MMP-9) [31]. The Foxo3a pathway is also found to induce TNBC cell death and cell cycle arrest by Qc. It increases Foxo3a nuclear translocation and protein level. JNK signaling pathway (activated upstream) is required to activate Foxo3a (JNK inhibitor suppresses the effect). The Foxo3a that is activated controls the factors of apoptosis (FasL) and cell cycle arrest (p53, p21, GADD45) [27]. Qc suppresses CYP3A4/Stat3 metabolic pathway in ER-positive BC. It inhibits the CYP3A4 activity, decreasing the synthesis of the arachidonic acid metabolites, which are epoxyeicosatrienoic acids (EETs). The decrease of the intracellular EETs inhibits phosphorylation and nuclear translocation of p-Stat3 (Tyr-705), which suppresses the growth of tumor cells [33]. On immune modulation, Qc influences cellular immunity through the JAK/STAT1 signaling pathway, where Qc elevates IFN7-R, p-JAK2, and p-STAT1 protein levels and lowers the immune checkpoint protein PD-L1 [29]. Finally, Qc is able to overcome Palbociclib (CDK4/6 inhibitor) resistance by adjusting circHIAT1/miR-19a-3p/CADM2 axis, by increasing circHIAT1 and CADM2 expression and reducing miR-19a-3p, which inhibits EMT [34]. Qc is also put forward to act like vitamin D3 by binding well to the Vitamin D receptor (VDR) which helps to prevent angiogenesis, inflammation and fibrosis [35]. Anticancer effects in colorectal cancer Apoptosis induction and survival pathway disruption in colorectal cancer Kaempferol shows promising anticancer activity against colorectal cancer by inducing apoptosis and disrupting key survival pathways. Li et al. [44] reported that it significantly reduced the viability of HCT-8 and HCT-116 cells in a dose-dependent manner, primarily by upregulating Bax, downregulating Bcl-2, and suppressing the PI3K/Akt signaling pathway. Notably, kaempferol also downregulated thymidylate synthase, suggesting potential to overcome 5-FU resistance. Supporting this, Kalyani et al. [45] demonstrated its selective cytotoxicity in HCT-15 cells, with minimal effects on normal lymphocytes and kidney cells, highlighting its preclinical efficacy signals. Kaempferol targets the OGT-Hsp47-collagen axis in colorectal cancer Recent mechanistic evidence further clarifies Kaempferol’s anticancer role in colorectal cancer through regulation of abnormal protein glycosylation. Zhou et al. [21] demonstrated that kaempferol exerts anticancer effects in colorectal cancer through modulation of the O-GlcNAcylation pathway. Using HCT116 cells at concentrations ranging from 20 µM (sub-toxic mechanistic concentration) to approximately 40 µM (IC₅₀), and treatment durations of 24 to 72 h, the study showed that kaempferol significantly inhibited CRC cell proliferation, migration, and colony formation. Mechanistically, kaempferol reduced intracellular UDP-GlcNAc levels and suppressed the activity of O-GlcNAc transferase (OGT) by directly binding to its catalytic residues His-901 and Asp-925, thereby disrupting the OGT-collagen signaling axis. This inhibition led to decreased O-GlcNAcylation of heat shock protein 47 (Hsp47), a collagen-specific molecular chaperone involved in extracellular matrix maturation and tumor invasiveness. As a result, kaempferol altered Hsp47 localization and reduced collagen secretion, ultimately impairing the tumor microenvironment. These findings highlight that kaempferol provides a pharmacological potential in colorectal cancer by targeting the OGT–Hsp47–collagen axis, expanding its known mechanisms beyond apoptosis and signaling pathway inhibition to include regulation of post-translational and metabolic processes. Quercetin and colorectal cancer The Qc in colorectal cancer (CRC) is transcriptionally regulated to target an angiogenesis axis, as well as critical proliferation/survival axes. Qc has anti-angiogenic properties, which inhibit the VEGF-A/VEGFR2 [26]. Meanwhile, in HT-29 CRC cells, the transcription factor NF-0065 and its target VEGF-A are suppressed by Qc, and in endothelial cells (HUVECs), VEGFR-2, the key factor in angiogenesis caused by CRC cells, is inhibited. Qc has a dual mechanism of action against protumoral Sp1-miR-27a axis to proliferate and survive (HCT116 and HT-29 cells). Qc suppresses key proliferation pathways (RAS/ERK, PI3K/AKT, and Wnt/β-catenin) through enhancing their negative regulators: Sprouty2 (SPRY2), PTEN, and SFRP1. The onco-miRNA miR-27a is lower on these negative regulators and is regulated by Qc, as well as the entire miR- 23a27a24-2 cluster nascent transcript, implying transcriptional control. It is through this transcriptional suppression that the transcription factor Sp1 is targeted. Qc represses Sp1 through two pathways: (1) silencing Sp1 through the upregulation of the repressive transcription factor ZBTB10 (an miR-27a target) and disrupting the auto-regulatory loop. (2) Sp1 protein becomes degraded through proteasome-mediated degradation induced by Qc following the rapid internalization into the nucleus. The central role of this mechanism is confirmed by the fact that Sp1 knockdown can recapitulate the effects of Qc [24]. Synergistic potential with conventional chemotherapies Kaempferol enhances the effectiveness of conventional chemotherapeutics by acting synergistically to promote the death of cancer cells. Kalyani et al. [45] reported that its combination with doxorubicin or cisplatin significantly increased apoptosis in breast and colorectal cancer cells, allowing lower doses of the cytotoxic agents. Correspondingly, Li et al. [44] found that kaempferol enhanced 5-FU-induced apoptosis in HCT-8 and HCT-116 cells by modulating Bax/Bcl-2 expression and suppressing the PI3K/Akt signaling pathway. Haroon and Kang [46] further confirmed its synergy with cisplatin, demonstrating enhanced ROS production, mitochondrial dysfunction, G1 arrest, and amplified apoptosis in colon cancer cells. Physiological relevance and translational considerations The use of supraphysiological concentrations in most in vitro studies limits the interpretation of the observed biological effects. Kaempferol and quercetin levels in most in vitro studies are usually higher than those attained by normal oral intake. These doses cannot be considered as translatable to clinical practices without specific mechanistic pharmacokinetic and bioavailability evaluation. Although rodent trials about quercetin have in vivo validation, dose-exposure relations and tumor tissue concentrations are not fully developed. Therefore, the recent evidence is in accordance with the biological plausibility but needs pharmacokinetic confirmation to specify clinically viable dosage regimen. The concentration of kaempferol and quercetin is often experimented at concentrations higher than those generally found in systemic circulation, which makes pharmacological plausibility questionable. As a result, these concentrations are effective in explaining the molecular mechanisms, but might not represent the in vivo conditions. This difference is especially important in considering the results of the induction of apoptosis, the inhibition of proliferation, and the regulation of epithelial-mesenchymal transition. The limited physiological relevance of the high in vitro concentration would require the strategies to focus on increasing the effective exposure at the target site. Nano-formulation methods such as lipid-based carriers and polymeric nanoparticles will be used to enhance the solubility of drugs and reduce their metabolism degradation rate, thus enhancing bioavailability and accumulating in tumors with increased permeability and retention. Prodrug strategies provide a solution with the adjustment of chemical structure of a parent compound to achieve the optimal absorption and systemic stability. After administration, these derivatives are enzymatically activated and the bioactive molecule is released in controlled way. This strategy can enable the achievement of better pharmacokinetics and less systemic loss. Moreover, the combination-based strategies are meant to take advantage of the synergistic effects of flavonoids and traditional anticancer agents. Through specific combinations of these, e.g., of complementary signaling pathways, e.g., of apoptosis control and inflammatory signaling, the effective concentration needed may be lowered to levels that do not affect biological activity. These are the strategies that are especially applicable in order to address the shortcomings of monotherapy at higher than physiological doses. Cross-cancer observations and limitations In all three types of cancer, quercetin and kaempferol seem to be pleiotropic agents interfering with many of the hallmarks of the disease, such as apoptotic evasion, proliferation, cell death resistance, and metastasis. Their comparatively low toxicity in non-cancerous cell lines is an extra advantageous factor to their therapeutic capabilities. Most studies reported dose-dependent efficacy; the concentration of these flavonoids required to elicit significant effects often exceeded physiologically achievable levels through diet alone. This demonstrates the necessity of future research studies on nano-formulations, prodrugs or synthetic derivatives to improve bioavailability and clinical applicability. The level of risk of bias was high in one of the studies, and in numerous other studies, it was not evident what risks were engaged in such areas as experimental replication, treatment reporting, and conflict of interest disclosure. In addition, not every discipline contains sufficient methodological data to limit the investigation of internal validity. A small bias may have been introduced through such concerns and it should come into play when interpreting the findings of the review. The limitation of this systematic review is the absence of in vivo animal or xenograft studies that matched our inclusion criteria to estimate the efficacy of kaempferol in lung, breast, or colorectal cancers. As a result, the review is based primarily on quercetin and only eight eligible in vivo studies exist, meaning that the prospective therapeutic value and mechanism knowledge of kaempferol in this kind of cancer is largely untested. Finally, purity, duration of treatment and methods of outcome assessment were not standardized among studies and direct comparison of flavonoids was not easy among those being studied. The lack of qualified in vivo kaempferol studies is obvious evidence of the gap in the existing evidence base and suggests more strictly designed preclinical studies in this field. The in vivo and clinical studies are still required to support the findings of the in vitro studies and to determine the therapeutic effects of these bioactive compounds with anticancer properties. Closing statement of discussion The overall results in this review indicate a high potential of pure quercetin and kaempferol as multi-targeted anticancer molecules, where they show homogenous results on lung, breast, and colorectal cancer cell lines. They have an added therapeutic potential through their capacity to mediate essential cellular functions, including the regulation of signaling, maintenance of oxidative stress, and control of metastasis. Although the available results are confined to in vitro (human cancer cell lines) and in vivo (animal models) experiments, the results are a valuable basis for future research in the context of translating their potential into clinically significant results. Research gaps Limited in vivo and clinical research- Although kaempferol and quercetin have demonstrated great anticancer activity in vitro, not enough supporting evidence has been provided by clinical trials. In the absence of this, its safety, bioavailability, and real therapeutic consequences in human body are unknown. Variability in experimental methods- Most of the studies vary in the method of application of these compounds with varying concentrations, exposure time, and cancer cell lines. The purity and source of the compound are also not provided in some instances, and it is thus hard to compare the results. Incomplete understanding of mechanisms- Although it has been determined that some of the pathways have been identified, more research must be conducted to have a complete understanding of the impact of kaempferol and quercetin on complex molecular signaling pathways, including PI3K/Akt, NF-kB, NRF2, and p53, especially in various and emerging types of cancer. Unclear effects on hormone-dependent and resistant cancers- The potential of the selected phytochemicals on hormone-sensitive and drug-resistant cells remains poorly clarified. Moreover, the effects of varying doses on their efficacy have not been determined. Lack of studies on real-world use and combinations- Insufficient research has been conducted on the comparison of kaempferol and quercetin as isolated compounds in natural food sources and purified supplements. Their possibilities to combine with other plant compounds or traditional therapies are also not well studied. Future research directions The future study must focus on the translation of the in vitro results on kaempferol and quercetin separately to a clinical outcome. It should also have a specific interest in conducting studies in order to determine their potential independent anticancer effects by conducting well-planned in vitro, in vivo, and clinical trials. The potential of kaempferol as an anti-cancer agent for breast, colorectal and lung cancer should be more focused and targeted in vivo research. Preclinical studies on the well-characterized in vivo models are required to investigate anticancer efficacy, mechanism of action, and safety of kaempferol in lung, breast and colorectal cancer. It will be required to translate it into clinical trials to figure out whether it is relevant as a treatment in human beings. The standardization of the experimental conditions, dosage, treatment duration, and endpoints in the research is required in the future to allow comparison and evidence-based inferences about the use of kaempferol as an anticancer agent. One of the main methods is the ability to consider them as a potential option when applied with the treatment methods of conventional cancer treatment, where they could improve the efficacy or prevent drug resistance. New therapeutic interventions may be discovered by further study of their interaction with hormonal signaling pathways, especially in hormone-sensitive cancer. Also, there is a significant potential for cancer prevention and supportive care associated with the incorporation of these flavonols into nutraceuticals or functional foods (particularly when it comes to co-administration with other bioactive compounds). In order to achieve the level of scientific rigor and comparability, future research should use well-documented, standardized in vitro and in vivo protocols that increase reproducibility and allow meaningful cross-study analysis. Conclusion This review shows the anticancer potential of single kaempferol and quercetin in vitro and in vivo (animal, xenograft models) of quercetin in lung, breast, and colorectal cancers. These cancer-modulating flavonoids have been indicated across the literature to lower viability of cancer cells, generate apoptosis, activate caspase-3, prevent Akt, mTOR, and ERK phosphorylation, and disrupt key cellular pathways related to cancer development. This evidence underlies their possible use as a natural compound of therapeutic value. The existing data points to the imbalance in the support of translation, as quercetin showed both in vitro and in vivo performance, whereas kaempferol is still backed up by cell-based research. This gap has to be resolved with strong in vivo studies to assist in defining its biological capability and therapeutic value. Additional studies beyond the in vitro studies that further involve pharmacological, molecular, and clinical studies will be necessary to bring them to significant usage in the prevention and treatment of cancer. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations Quercetin Bcl-2-associated X protein B-cell lymphoma 2 Cell counting kit-8 Gap 2/mitosis cell cycle phase Human epidermal growth factor receptor 2 Mitogen-activated protein kinase Phosphoinositide 3-kinase Ribosomal protein S6 kinase Triple-negative breast cancer Vascular endothelial growth factor Poly (ADP-ribose) polymerase Author contributions M.T.S and A.A conceptualized the review. B.S, A.M.N and I.N conducted the literature search, and drafted the manuscript. M.M and A.F contributed to the critical analysis of the selected studies and provided input on the structure and interpretation. T.F.Y and H.R reviewed and edited the manuscript for intellectual content and supervised the overall project. All authors read and approved the final manuscript. Funding No funding was received for this manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Ahmad Mujtaba Noman, Email: ahmadmujtaba493@gmail.com. Tadesse Fenta Yehuala, Email: tadese.fenta@bdu.edu.et. Hassan Raza, Email: sh.raza40@yahoo.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement No datasets were generated or analysed during the current study.